Trav7d-3 Inhibitors
Trav7d-3 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the Trav7d-3 gene segment, which encodes a variable region of the T-cell receptor (TCR) alpha chain. This gene segment plays a crucial role in the diversity of T-cell receptors, which are essential for the adaptive immune system's ability to recognize a wide variety of antigens presented by MHC molecules. By inhibiting Trav7d-3, these compounds disrupt the assembly of TCRs that contain this particular variable segment, potentially affecting antigen recognition and T-cell activation.
The chemical design of Trav7d-3 inhibitors focuses on interfering with the gene's expression or its integration into the TCR complex. These inhibitors may act by binding to specific regions of the Trav7d-3 gene or by blocking the protein interactions that facilitate its incorporation into functional T-cell receptors. Researchers study Trav7d-3 inhibitors to gain insights into the role of this specific variable segment in immune recognition and how altering its function affects the overall adaptability and specificity of the immune response. Through this research, scientists aim to better understand the intricate mechanisms by which TCR diversity is generated and regulated, with a focus on antigen specificity and immune system behavior.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A may inhibit T cell receptor alpha variable 7D-3 expression by blocking calcineurin, an enzyme essential for the activation of NFAT transcription factors involved in T cell receptor signaling. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Tacrolimus may inhibit T cell receptor alpha variable 7D-3 expression by binding to FK506-binding protein 12, leading to inhibition of calcineurin and subsequent downregulation of T cell receptor signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit T cell receptor alpha variable 7D-3 expression by binding to FKBP12 and inhibiting mTOR, a key regulator of T cell activation and proliferation, leading to suppression of downstream signaling necessary for its expression. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid may inhibit T cell receptor alpha variable 7D-3 expression by inhibiting inosine monophosphate dehydrogenase, reducing the synthesis of guanosine nucleotides required for T cell activation and proliferation. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus may inhibit T cell receptor alpha variable 7D-3 expression by binding to FKBP12 and inhibiting mTOR, a central regulator of T cell activation and proliferation pathways, leading to suppression of its downstream signaling. | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
Fingolimod may inhibit T cell receptor alpha variable 7D-3 expression by modulating sphingosine-1-phosphate receptors, sequestering T cells in lymphoid organs and preventing their activation, thereby inhibiting its expression. | ||||||